Combined modality immunotherapy and chemotherapy: a new perspective.
The results of recent clinical trials have demonstrated that cancer vaccines continue to struggle to achieve tangible clinical benefits as monotherapy. Tumor-induced abnormalities in the immune system hamper anti-tumor T cell responses limiting the effectiveness of cancer immunotherapy. Recently, evidence has been mounting to suggest that immunotherapy has the possibility of achieving better success when used in combination with conventional chemotherapy. In clinical trials, immune responses elicited by cancer vaccines appear to augment the effectiveness of subsequent conventional cancer therapies.
Ramakrishnan
Rupal
R
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Antonia
Scott
S
Gabrilovich
Dmitry I
DI
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D019496:Cancer Vaccines / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D009369:Neoplasms / Q000628:therapy*
D000970:Antineoplastic Agents; D019496:Cancer Vaccines